Objective To analyze the value of combining oxaliplatin and capecitabine in the treatment of colorectal cancer.Methods A total of 185 colorectal cancer patients admitted to Suzhou Municipal Hospital from August 2022 to January 2024 were selected as the study subjects,which were divided into control group(92 cases treated with capecitabine)and observation group(93 cases treated with oxaliplatin and capecitabine).The clinical efficacy,immune function,biological behavioral indicators,and tumor markers were compared be-tween the two groups.Results The clinical efficacy of the observation group(67.74%)was higher than that of the control group(52.17%),and the difference was statistically significant(χ2=4.043,P<0.05);CD3+,CD4+,CD4+/CD8+of the observation group were higher than that of the observation group,and the differences were statistically significant(all P<0.05).The levels of Collagen triple helix repeat protein 1,protein-like type 3 pro-tein and survival protein in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).The levels of carcinoembryonic antigen and carbohydrate antigen 199 in ob-servation group were lower than those in control group,and the differences were statistically significant(both P<0.05).Conclusion Oxaliplatin-capecitabine combination significantly improves the immune function and tu-mor marker level in colon cancer patients,and can reduce other medical costs.
维普
万方数据